Talis Biomedical

Talis Biomedical

Molecular diagnostic tests for infectious diseases

About Talis Biomedical

Simplify's Rating
Why Talis Biomedical is rated
C+
Rated D- on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

11-50

Company Stage

IPO

Headquarters

California

Founded

2010

Overview

Talis Biomedical provides molecular diagnostic tests that are easy to use and designed for detecting infectious diseases, particularly COVID-19. Their tests allow for rapid and accurate results to be obtained directly at the point of care, such as hospitals and clinics, where patients receive treatment. This is important for healthcare providers who need timely information to make decisions about patient care. Talis's main product, the Talis One COVID-19 Test System, can accurately detect the SARS-CoV-2 virus and its variants, including Omicron. Unlike many competitors, Talis focuses on delivering lab-quality results quickly at the location of care, which helps improve patient outcomes and manage the spread of diseases. The company's goal is to enhance the accessibility and efficiency of molecular diagnostics in healthcare.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for decentralized healthcare boosts Talis's point-of-care testing solutions.
  • Advancements in microfluidics align with Talis's compact diagnostic devices.
  • Regulatory fast-tracking may accelerate Talis's product launch timelines.

What critics are saying

  • Increased competition from established companies like Abbott and Roche.
  • Class action lawsuits could lead to financial liabilities and reputational damage.
  • Closure of Redwood City labs may disrupt operations and delay product development.

What makes Talis Biomedical unique

  • Talis offers rapid, point-of-care molecular diagnostics for infectious diseases.
  • The Talis One platform is cloud-enabled, allowing real-time data sharing and integration.
  • Talis focuses on lab-quality results at the point of care, enhancing healthcare delivery.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8.6M

Above

Industry Average

Funded Over

1 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-11%

2 year growth

17%
Compsmag
Jan 2nd, 2024
Tech and Biotech Layoffs Rock Bay Area Job Market: Staff Cutbacks Widen

Talis Biomedical is planning 103 job cuts in Redwood City.

Compsmag
Jan 2nd, 2024
Tech and Biotech Layoffs Rock Bay Area Job Market as Staff Cutbacks Widen

As well as to Western Digital's job cuts in Milpitas, Talis Biomedical is planning to cut 103 jobs in Redwood City due to the permanent closure of its laboratories and offices.

BioSpace
Aug 2nd, 2023
Talis Biomedical Announces Andrew Lukowiak, Ph.D., As President And Chief Scientific Officer (Cso)

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platform engineering, operations, regulatory and clinical affairs functions for Talis Biomedical.“We are thrilled to welcome Andrew to our leadership team as we continue to develop the Talis One® test menu and plan to initiate clinical studies to support our pursuit of multiple 510(k) clearances,” said Rob Kelley,” chief executive officer at Talis Biomedical

Hit Consultant
May 26th, 2023
Recent Digital Health Executive Hires & Board Appointments

Practice Better announced that Kim Walsh will be stepping in as CEO and Nathalie Garcia, Co-Founder of Practice Better, will step into a new role as Chief Strategy Officer where she will continue serving Practice Better’s customers, employees, partners, and investors while supporting and advising Kim in her new role.HHAeXchange has appointed Paul Joiner as Chief Executive Officer. The new CEO’s appointment also further advances HHAeXchange’s commitment to innovation in its product roadmap and platform expansion, which will enable better technology in the home, improve care collaboration, and drive more efficient workflows.Intelerad Medical Systems™ announced the retirement of CEO Mike Lipps, who served the company for nearly three years as part of a 20-plus year software industry career, and is handing the organization’s global team and mission over to Mr. Jordan Bazinsky as the new Chief Executive Officer.Carteret Health appoints Kyle Marek as CEO after serving for more than five months as the hospital’s interim CEO.Cynerio appoints Rasu B. Shrestha, MD, MBA as Chairman of the Board for Cynerio. Dr. Shrestha brings extensive experience in healthcare innovation and commercialization to Cynerio, including spearheading a renewed focus on innovation at Advocate Health and launching new healthcare inventions, discoveries, and ideas to benefit patients and communities.Tegria, appoints Jen Morgan as its chief financial officer, and Prasanna Gunjikar as its chief growth officer. Atlas Healthcare Partners promotes Dan Jones to Chief Operating Officer and names Jessie Monnier as Market President to accelerate growth and leadership.CRISP Shared Services (CSS) names Marc Rabner, MD, MPH as its first-ever chief medical officer (CMO)

BioSpace
May 24th, 2023
Talis Biomedical Appoints Former Roche Molecular Ceo Heiner Dreismann To Board Of Directors, Announces Former Genomic Health Ceo Kim Popovits As Lead Independent Director | Biospace

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.“Heiner’s entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is pursuing,” said Rob Kelley, chief executive officer at Talis Bio. “We look forward to benefiting from Heiner’s seasoned perspective and Kim’s continued support as we execute our plan to deliver multiple women’s and sexual health tests at the point of care.”Dr. Dreismann has more than 35 years of experience in the diagnostic industry and is regarded as a pioneer in the early adoption of polymerase chain reaction (PCR) technique. From 1985 to 2006, he held multiple executive positions at Roche Diagnostics, including president and chief executive officer of Roche Molecular Systems, head of global business development of Roche Diagnostics and member of Roche’s Global Diagnostic Executive Committee. Dr

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Talis Biomedical right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →